-$0.30 EPS Expected for Unity Biotechnology Inc (UBX) This Quarter
Equities research analysts expect Unity Biotechnology Inc (NASDAQ:UBX) to report earnings per share (EPS) of ($0.30) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Unity Biotechnology’s earnings. The company is expected to issue its next earnings report on Thursday, November 8th.
On average, analysts expect that Unity Biotechnology will report full year earnings of ($1.19) per share for the current fiscal year. For the next financial year, analysts forecast that the firm will report earnings of ($1.58) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Unity Biotechnology.
Unity Biotechnology (NASDAQ:UBX) last posted its quarterly earnings results on Thursday, August 9th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.38).
Institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp purchased a new position in Unity Biotechnology in the second quarter worth approximately $168,000. Citadel Advisors LLC purchased a new position in Unity Biotechnology in the second quarter worth approximately $230,000. Gilder Gagnon Howe & Co. LLC purchased a new position in Unity Biotechnology in the second quarter worth approximately $301,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Unity Biotechnology during the second quarter worth $309,000. Finally, Dean Capital Investments Management LLC purchased a new position in shares of Unity Biotechnology during the second quarter worth $543,000. Institutional investors own 30.25% of the company’s stock.
Shares of NASDAQ:UBX traded down $0.53 during midday trading on Friday, hitting $13.87. The company had a trading volume of 138,809 shares, compared to its average volume of 140,064. Unity Biotechnology has a twelve month low of $12.75 and a twelve month high of $24.56.
Unity Biotechnology Company Profile
Unity Biotechnology, Inc, a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases.
Featured Article: Trading Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.